Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Amongst sufferers with beforehand untreated, PD-L1-positive metastatic triple-negative breast most cancers (mTNBC), therapy with Trodelvy (sacituzumab govitecan) plus Keytruda (pembrolizumab) has been...
Camrelizumab together with famitinib produced superior progression-free survival (PFS) outcomes versus platinum-based chemotherapy for the frontline therapy of sufferers with recurrent or...
Adjuvant therapy with Alecensa (alectinib) elicited a 4-year total survival (OS) fee of 98.4% for sufferers with resected ALK-positive early stage non–small...
Amongst sufferers with treatment-naïve superior melanoma, therapy with the investigational immune-modulatory therapeutic most cancers vaccine IO102-IO103 plus Keytruda (pembrolizumab) has been discovered...
